Insights from 2024 EHA Annual Meeting

 

Insights from 2024 EHA Annual Meeting
S

Highlights in Plasma Cell Disorders From ASCO® and EHA

By Insights from 2024 EHA Annual Meeting FEATURING Samer Al Hadidi
By Insights from 2024 EHA Annual Meeting FEATURING Samer Al Hadidi
85 views
June 27, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

01:29
Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Videos
14:32
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Infectious Complications in BCMA- and GPRC5D-Targ…

Feat. J. Mersi
03:52
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: FLAG-GO vs. FLAG-IDA in Untreated Core Binding Fa…

Feat. G. Borthakur
04:03
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: PROs After Epcoritamab in R/R Follicular Lymphoma

Feat. W. Jurczak
05:27
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Updated Trends in Real-World Outpatient Administr…

Feat. R. Bansal
06:39
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Axicabtagene Ciloleucel in R/R Primary Mediastina…

Feat. J. Galtier
12:32
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Sequential Administration of Bispecific Antibodie…

Feat. D. Fandrei
06:51
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: SYMPATICO Study - Ibrutinib + Venetoclax in MCL W…

Feat. W. Jurczak
10:03
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: SEQUOIA Trial Arm D - Zanubrutinib + Venetoclax f…

Feat. P. Ghia
12:04
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: The Impact of TP53 Mutation Burden on Risk & …

Feat. M. Salamoon
06:54
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: CD20-Targeted CAR-T Therapy for BTKi-Refractory W…

Feat. M. Shadman
05:41
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Advantages of Using Venetoclax-Based Therapy in H…

Feat. C. Coombs
06:30
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: QuANTUM-First Trial - Newly Diagnosed FLT3-ITD+ A…

Feat. E. Oliva
11:23
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Final 5-Year Results of Olutasidenib for Mutated …

Feat. J. Cortés
14:39
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: REVIVE Study - Updated Long-Term Results of Hepci…

Feat. K. Pettit
04:33
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Daratumumab for iTTP

Feat. J. Weisinger
36:10
Insights from 2024 EHA Annual Meeting

Highlights in Plasma Cell Disorders From ASCO® and EHA

Feat. S. Al Hadidi
09:52
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: AML Highlights - Focus on Menin Inhibitors

Feat. J. Zeidner
11:40
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: FLAG-IDA + Venetoclax in Newly Diagnosed or R/R A…

Feat. W. Jen
10:27
Insights from 2024 EHA Annual Meeting

Responder Analysis From the PhALLCON Trial: Ponatinib vs. Imatinib i…

Feat. J. Ribera
19:14
2024 ASCO® Annual Meeting Insights Hub

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

Feat. K. Rogers, J. Woyach
07:38
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: TRANSCEND NHL 001 Study - Liso-Cel in R/R MCL - A…

Feat. M. Kamdar
12:24
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: PERSEUS Trial MRD Analysis: Dara + VRd in Transpl…

Feat. P. Sonneveld
12:00
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: QUAZAR AML-001 - Oral Azacitidine Maintenance in …

Feat. M. Teresa Voso